Cardiff Oncology Past Earnings Performance
Past criteria checks 0/6
Cardiff Oncology's earnings have been declining at an average annual rate of -19.8%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.2% per year.
Key information
-19.8%
Earnings growth rate
26.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 18.2% |
| Return on equity | -87.0% |
| Net Margin | -6,250.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cardiff Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -43 | 12 | 0 |
| 30 Jun 24 | 1 | -41 | 12 | 0 |
| 31 Mar 24 | 1 | -40 | 13 | 0 |
| 31 Dec 23 | 0 | -41 | 13 | 0 |
| 30 Sep 23 | 0 | -41 | 13 | 0 |
| 30 Jun 23 | 0 | -40 | 14 | 0 |
| 31 Mar 23 | 0 | -39 | 12 | 0 |
| 31 Dec 22 | 0 | -39 | 13 | 0 |
| 30 Sep 22 | 0 | -39 | 14 | 0 |
| 30 Jun 22 | 0 | -38 | 14 | 0 |
| 31 Mar 22 | 0 | -34 | 14 | 0 |
| 31 Dec 21 | 0 | -28 | 12 | 0 |
| 30 Sep 21 | 0 | -25 | 11 | 0 |
| 30 Jun 21 | 0 | -23 | 10 | 0 |
| 31 Mar 21 | 0 | -24 | 9 | 0 |
| 31 Dec 20 | 0 | -23 | 8 | 0 |
| 30 Sep 20 | 0 | -20 | 6 | 0 |
| 30 Jun 20 | 0 | -20 | 6 | 0 |
| 31 Mar 20 | 0 | -17 | 6 | 0 |
| 31 Dec 19 | 0 | -17 | 6 | 0 |
| 30 Sep 19 | 0 | -17 | 6 | 0 |
| 30 Jun 19 | 0 | -16 | 6 | 0 |
| 31 Mar 19 | 0 | -19 | 7 | 0 |
| 31 Dec 18 | 0 | -19 | 8 | 0 |
| 30 Sep 18 | 0 | -18 | 8 | 0 |
| 30 Jun 18 | 1 | -18 | 11 | 0 |
| 31 Mar 18 | 1 | -20 | 11 | 0 |
| 31 Dec 17 | 1 | -25 | 12 | 0 |
| 30 Sep 17 | 0 | -31 | 14 | 0 |
| 30 Jun 17 | 0 | -37 | 16 | 0 |
| 31 Mar 17 | 0 | -39 | 19 | 0 |
| 31 Dec 16 | 0 | -39 | 22 | 0 |
| 30 Sep 16 | 0 | -38 | 22 | 0 |
| 30 Jun 16 | 0 | -31 | 21 | 0 |
| 31 Mar 16 | 0 | -31 | 19 | 0 |
| 31 Dec 15 | 0 | -27 | 14 | 0 |
| 30 Sep 15 | 0 | -25 | 14 | 0 |
| 30 Jun 15 | 0 | -27 | 12 | 0 |
| 31 Mar 15 | 0 | -18 | 10 | 0 |
| 31 Dec 14 | 0 | -14 | 9 | 0 |
| 30 Sep 14 | 0 | -11 | 7 | 0 |
| 30 Jun 14 | 0 | -10 | 8 | 0 |
| 31 Mar 14 | 0 | -14 | 7 | 0 |
| 31 Dec 13 | 0 | -12 | 7 | 0 |
Quality Earnings: XE7C is currently unprofitable.
Growing Profit Margin: XE7C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XE7C is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare XE7C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XE7C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: XE7C has a negative Return on Equity (-87.02%), as it is currently unprofitable.